Earnings History Data for Aquestive Therapeutics (AQST) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Aquestive Therapeutics

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
05-03-2024	PM		AQST	Aquestive Therapeutics	245.00	-0.12	-0.08	0.00	Aquestive Therapeutics reports mixed Q4 results; initiates FY24 outlook [3/6/2024 12:58 AM]	5.07	0.88 (21.00%)	4.10	-0.09 (-2.15%)	0.72 - 5.19	6,696,551	3,390,000	151,901
Aquestive Therapeutics reports mixed Q4 results; initiates FY24 outlook [3/6/2024 12:58 AM]
06-11-2023	AH		AQST	Aquestive Therapeutics, Inc.	88.89	-0.03	-0.11	-0.23	Aquestive Therapeutics GAAP EPS of -$0.03 beats by $0.09, revenue of $13M beats by $1.49M [11/6/2023 4:55 PM]	1.73	0.10 (6.13%)	1.64	0.01 (0.61%)	0.72 - 2.69	211,189	170,000	7,128
Aquestive Therapeutics GAAP EPS of -$0.03 beats by $0.09, revenue of $13M beats by $1.49M [11/6/2023 4:55 PM]
07-08-2023	AH		AQST	Aquestive Therapeutics, Inc.	121.91	-0.10	-0.11	-0.36	Aquestive Therapeutics GAAP EPS of -$0.10 beats by $0.01, revenue of $13.24M beats by $2.23M [8/7/2023 4:05 PM]	1.97	-0.08 (-3.90%)	2.02	-0.03 (-1.46%)	0.72 - 2.69	686,967	610,000	14,394
Aquestive Therapeutics GAAP EPS of -$0.10 beats by $0.01, revenue of $13.24M beats by $2.23M [8/7/2023 4:05 PM]
02-05-2023	AH	4:00 PM ET (May 2)	AQST	Aquestive Therapeutics, Inc.	70.96	0.11	-0.10	-0.32	Aquestive Therapeutics reports Q1 results, raises FY 2023 revenue guidance [5/2/2023 5:11 PM]	1.70	0.31 (21.94%)	1.40	0.01 (0.72%)	0.62 - 1.80	1,434,919	220,000	6,877
Aquestive Therapeutics reports Q1 results, raises FY 2023 revenue guidance [5/2/2023 5:11 PM]
07-03-2023	AH	4:00 PM ET (Mar 7)	AQST	Aquestive Therapeutics, Inc.	42.27	-0.23	-0.21	-0.38	Aquestive Therapeutics GAAP EPS of -$0.23 in-line, revenue of $10.68M beats by $0.26M [3/7/2023 4:05 PM]	0.86	0.01 (1.18%)	0.82	-0.02 (-2.94%)	0.62 - 2.95	468,475	300,000	5,475
Aquestive Therapeutics GAAP EPS of -$0.23 in-line, revenue of $10.68M beats by $0.26M [3/7/2023 4:05 PM]
01-11-2022	AH	4:00 PM ET (Nov 1)	AQST	Aquestive Therapeutics, Inc.	45.88	-0.23	-0.30	-0.37	Aquestive Therapeutics GAAP EPS of -$0.23 beats by $0.07, revenue of $11.46M beats by $0.42M [11/1/2022 4:42 PM]	0.8349	-0.02 (-2.41%)	0.90	0.04 (4.85%)	0.62 - 6.40	318,985	310,000	6,828
Aquestive Therapeutics GAAP EPS of -$0.23 beats by $0.07, revenue of $11.46M beats by $0.42M [11/1/2022 4:42 PM] Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update [Nov-01-22 04:01PM] Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates [Nov-01-22 05:15PM]
02-08-2022	AH	5:40 PM ET (Aug 2)	AQST	Aquestive Therapeutics, Inc.	44.74	-0.36	-0.41	-0.33	Aquestive Therapeutics GAAP EPS of -$0.36 in-line, revenue of $13.27M beats by $2.7M [8/2/2022 5:02 PM]	0.8379	-0.04 (-4.75%)	0.92	0.04 (4.58%)	0.62 - 6.40	693,418	340,000	795
Aquestive Therapeutics GAAP EPS of -$0.36 in-line, revenue of $13.27M beats by $2.7M [8/2/2022 5:02 PM] Shares of Aquestive Therapeutics fall after Q2 revenue decreases, loss widens [8/3/2022 11:16 AM] Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update [Aug-02-22 04:02PM] Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates [Aug-02-22 05:15PM]
03-05-2022	AH	4:55 PM ET (May 3)	AQST	Aquestive Therapeutics	58.00	-0.32	-0.45	0.00	Aquestive Therapeutics GAAP EPS of -$0.32 beats by $0.09, revenue of $12.27M beats by $2.15M [5/3/2022 5:48 PM]	1.43	0.06 (4.38%)	1.49	0.12 (8.76%)	1.25 - 6.40	452,866	410,000	3,653
Aquestive Therapeutics GAAP EPS of -$0.32 beats by $0.09, revenue of $12.27M beats by $2.15M [5/3/2022 5:48 PM] Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update [May-03-22 05:41PM] Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates [May-03-22 06:55PM] Aquestive Therapeutics, Inc. (AQST) Q1 2022 Earnings Call Transcript [May-04-22 02:30PM]
08-03-2022	AH	4:30 PM ET (Mar 8)	AQST	Aquestive Therapeutics, Inc.	116.48	-0.38	-0.37	-0.60	Aquestive Therapeutics GAAP EPS of -$1.85 misses by $0.36, revenue of $50.83M beats by $1.73M [3/8/2022 5:07 PM]	2.86	0.04 (1.42%)	2.75	-0.07 (-2.48%)	2.02 - 6.40	211,626	330,000	336
Aquestive Therapeutics GAAP EPS of -$1.85 misses by $0.36, revenue of $50.83M beats by $1.73M [3/8/2022 5:07 PM] Aquestive Therapeutics Reports Full Year 2021 Results Exceeding Revenue and EBITDA Guidance [Mar-08-22 04:56PM] Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates [Mar-08-22 06:15PM] Aquestive Therapeutics, Inc. (AQST) Q4 2021 Earnings Call Transcript [Mar-09-22 05:30PM]
02-11-2021	AH	5:55 PM ET (Nov 2)	AQST	Aquestive Therapeutics, Inc.	196.38	-0.37	-0.40	-0.49	Aquestive Therapeutics EPS beats by $0.06, beats on revenue [11/2/2021 5:17 PM]	5.92	0.56 (10.45%)	5.30	-0.06 (-1.12%)	3.10 - 8.06	1,344,355	750,000	10,110
Aquestive Therapeutics EPS beats by $0.06, beats on revenue [11/2/2021 5:17 PM] Aquestive Therapeutics, Inc. (NASDAQ:AQST) Is Expected To Breakeven In The Near Future [Nov-02-21 07:04AM] Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance [Nov-02-21 04:30PM] Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates [Nov-02-21 06:35PM] Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Call Transcript [Nov-03-21 08:01PM]
03-08-2021	AH	7:55 PM ET (Aug 3)	AQST	Aquestive Therapeutics, Inc.	118.92	-0.33	-0.42	-0.07	Aquestive Therapeutics EPS beats by $0.10, beats on revenue [8/3/2021 5:57 PM]	3.67	0.42 (12.92%)	3.48	0.23 (7.08%)	3.10 - 9.46	2,700,110	260,000	111,334
Aquestive Therapeutics EPS beats by $0.10, beats on revenue [8/3/2021 5:57 PM] Aquestive beats Q2 estimates; FY21 revenue guidance raise tops consensus [8/4/2021 1:58 AM] Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue Guidance [Aug-03-21 05:55PM] Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates [Aug-03-21 07:25PM]
04-05-2021	AH	5:50 PM ET (May 4)	AQST	Aquestive Therapeutics, Inc.	148.84	-0.41	-0.44	-0.49	Aquestive Therapeutics EPS beats by $0.01, beats on revenue [5/4/2021 11:44 PM]	3.85	0.20 (5.48%)	3.85	0.20 (5.48%)	3.57 - 9.46	564,095	570,000	2,832
Aquestive Therapeutics EPS beats by $0.01, beats on revenue [5/4/2021 11:44 PM] Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update [May-04-21 07:53PM] Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates [May-04-21 08:25PM] Aquestive Therapeutics, Inc. to Host Earnings Call [May-05-21 06:15AM]
09-03-2021	AH	4:30 PM ET (Mar 9)	AQST	Aquestive Therapeutics, Inc.	148.26	-0.60	-0.46	-0.48	Aquestive Therapeutics EPS misses by $0.10, beats on revenue [3/9/2021 6:01 PM]	4.76	0.29 (6.49%)	4.35	-0.12 (-2.68%)	1.41 - 9.46	864,252	1,134,667	33,041
Aquestive Therapeutics EPS misses by $0.10, beats on revenue [3/9/2021 6:01 PM] ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline AQST [Mar-08-21 04:46PM] SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Mar-08-21 12:30PM] Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors [Mar-08-21 12:00PM] The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors [Mar-08-21 11:10AM] Aquestive Therapeutics Earnings Preview [Mar-08-21 10:07AM] AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm [Mar-08-21 10:00AM] AQST Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm [Mar-09-21 10:00AM] INVESTOR DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Mar-09-21 11:10AM] Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update [Mar-09-21 05:49PM] Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates [Mar-09-21 07:05PM] Aquestive Therapeutics, Inc. to Host Earnings Call [Mar-10-21 05:15AM] ROSEN, A TOP RANKED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline AQST [Mar-10-21 10:00AM] AQST Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm [Mar-10-21 10:00AM] SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Mar-10-21 11:45AM] Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST) [Mar-10-21 01:00PM] Aquestive Therapeutics, Inc. (AQST) Q4 2020 Earnings Call Transcript [Mar-10-21 01:30PM]
04-11-2020	AH	4:00 PM ET (Nov 4)	AQST	Aquestive Therapeutics, Inc.	161.38	-0.49	-0.50	-0.54	Aquestive Therapeutics EPS misses by $0.04, misses on revenue, revised FY20 guidance [11/4/2020 4:49 PM]	5.46	0.18 (3.41%)	5.11	-0.17 (-3.22%)	1.41 - 10.00	768,823	516,278	3,443

04-08-2020	AH	4:05 PM ET (Aug 4)	AQST	Aquestive Therapeutics, Inc.	176.64	-0.07	-0.43	-0.82	Aquestive Therapeutics EPS beats by $0.36, beats on revenue [8/4/2020 4:13 PM]	6.08	0.59 (10.75%)	5.83	0.34 (6.19%)	1.41 - 10.00	715,836	573,397	19,106

05-05-2020	AH	4:30 PM ET (May 5)	AQST	Aquestive Therapeutics, Inc.	140.04	-0.49	-0.52	-0.59	Aquestive Therapeutics EPS misses by $0.04, misses on revenue [5/5/2020 4:15 PM]	4.50	0.0 (0.00%)	4.55	0.05 (1.11%)	1.41 - 10.00	790,262	744,864	2,974